In some cancers, circulating lymphangiogenic factors are increased compared to healthy individuals or patients with benign tumours, for example, VEGF-C in lung non-small-cell carcinoma (Tamura and Ohta, 2003). This evidence concerns the gene VEGFC and non-small cell lung carcinoma.